Palantir's Playbook Being Copied, But Valuation Still Demands Proof of Conversion

What happened

The MarketBeat article notes that industry players are increasingly copying Palantir's integrated AI deployment approach, which validates the strategy but also signals emerging competitive pressure. This comes as Palantir's latest filings show exceptional growth—Q2 2026 revenue up 93% Y/Y to $1.94B with 85% gross margin—but soft hard-backlog conversion, with company-wide RPO at $4.9B versus $6.24B in U.S. commercial remaining deal value and many contracts terminable for convenience. Revenue also remains heavily concentrated, with 80% from U.S. customers, and the stock trades at 147x P/E and 252x EV/EBITDA, leaving no margin of safety. The article's implication that Palantir's playbook is being copied reinforces the risk that its moat may erode as competitors adopt similar bundling, though execution so far remains strong. The next two quarterly filings will be critical to see whether bookings convert into deferred revenue and RPO growth, or whether the valuation resets.

Implication

Investors should maintain current positions but resist adding at today's price near $186, given the extreme valuation and crowded narrative. The primary monitor is whether company-wide RPO, deferred revenue, and customer deposits grow in line with commercial deal activity; if they flatten while TCV/RDV remain strong, the thesis weakens. Additionally, watch the Pentagon's proposed up-to-$244M action for clean conversion and non-U.S. revenue mix for signs of international expansion. If RPO exceeds $5.8B within two quarters and non-U.S. revenue rises above 22%, the case for higher valuation strengthens. Conversely, if RPO stays below $5.0B and procurement delays surface, consider trimming positions.

Thesis delta

The article does not change the fundamental thesis but highlights that Palantir's approach is being widely copied, which could accelerate competitive erosion even as it validates demand. The core unresolved issue remains from the master report: whether headline deal values convert into hard, recognizable backlog quickly enough to support the stock's premium. No shift in rating is warranted; maintain WAIT and conviction level 4.